Enlila Health, a venture capital firm, has become the primary partner of Crescenta Biosciences.

▤ Summary

Enlila Health, backed by İş Girişim Sermayesi and tied to Harvard University, acquired 50.1% of Crescenta Biosciences for $24 million. The transaction has closed and the related capital increase was completed. The deal expands Enlila’s biotechnology strategy onto an international stage and links its academic and financial base with Crescenta’s discovery platform. Crescenta will use the partnership to accelerate its innovative biotech solutions, deep-tech health projects, and clinical programs.

▦ Linked Companies